SMARCA2 and neoplasm: Combinations of the BET inhibitor OTX015 that targets BET family member BRD2 (bromodomain containing 2) and MEK (mitogen-activated protein kinase kinase) inhibitors have also shown efficacy in preclinical models of SCCOHT, although this does not appear to be specific for tumours with concomitant SMARCA4 and SMARCA2 loss [167].